Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:public_company |
| gptkbp:CEO |
gptkb:John_Evans
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusArea |
oncology
hematology genetic diseases liver diseases rare diseases |
| gptkbp:foundedYear |
2017
|
| gptkbp:founder |
gptkb:David_R._Liu
gptkb:Feng_Zhang gptkb:John_Evans gptkb:J._Keith_Joung |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Beam Therapeutics Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:IPODate |
2020
|
| gptkbp:notableCollaboration |
gptkb:Pfizer
gptkb:Apellis_Pharmaceuticals gptkb:Verve_Therapeutics |
| gptkbp:notableProduct |
base editors
|
| gptkbp:numberOfEmployees |
over 300
|
| gptkbp:platform |
gptkb:CRISPR
|
| gptkbp:specializesIn |
gene editing
base editing |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:BEAM
|
| gptkbp:website |
https://www.beamtx.com/
|
| gptkbp:bfsParent |
gptkb:NASDAQ:_BEAM
|
| gptkbp:bfsLayer |
6
|